--- title: "Sellas Life Sciences (SLS.US) — Financial Reports" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/SLS.US/norm.md" symbol: "SLS.US" name: "Sellas Life Sciences" parent: "https://longbridge.com/en/quote/SLS.US.md" datetime: "2026-05-21T20:56:45.811Z" locales: - [en](https://longbridge.com/en/quote/SLS.US/norm.md) - [zh-CN](https://longbridge.com/zh-CN/quote/SLS.US/norm.md) - [zh-HK](https://longbridge.com/zh-HK/quote/SLS.US/norm.md) --- # Sellas Life Sciences (SLS.US) — Financial Reports ## Income Statement (USD) | Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | | --- | --- | --- | --- | --- | --- | | EPS | -0.0487 | -0.0542 | -0.0626 | -0.0700 | -0.0662 | | ROE | -37.72% | -52.59% | -75.69% | -97.96% | -124.93% | | Revenue | - | - | - | - | - | | Net income | -8.41M | -7.66M | -6.79M | -6.60M | -5.81M | | Operating income | -9.25M | -7.16M | -7.08M | -6.87M | -6.06M | | Gross margin | - | - | - | - | - | | Net margin | - | - | - | - | - | | Profit quality | - | - | - | - | - | ## Balance Sheet (USD) | Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | | --- | --- | --- | --- | --- | --- | | A&L | 114.18M | 78.34M | 51.55M | 32.30M | 34.96M | | Leverage | 1.06 | 1.11 | 1.13 | 1.24 | 1.26 | | BVPS | 0.5923 | 0.4629 | 0.3648 | 0.2605 | 0.3054 | | Turnover | - | - | - | - | - | | Cash & STI | 107.10M | 71.79M | 44.32M | 25.30M | 28.40M | | Inv & Rec | - | - | - | - | - | | LT assets | 839000.00 | 963000.00 | 556000.00 | 683000.00 | 806000.00 | | Net debt | -106.23M | -70.79M | -43.72M | -24.56M | -27.53M | ## Cash Flow Statement (USD) | Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | | --- | --- | --- | --- | --- | --- | | Operating CF | -8.85M | -4.92M | -7.07M | -7.33M | -9.07M | | Investing CF | - | - | - | - | - | | Financing CF | 44.15M | 32.39M | 26.09M | 4.23M | 23.58M | | Free CF | -6.22M | -1.56M | -4.60M | -5.28M | -7.06M | | OCF coverage | - | - | - | - | - | | Repaid & issued | - | - | - | - | - | | CapEx | - | - | - | - | - |